In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma

Study demonstrates MEK and RAF/MEK inhibitors effectively suppress growth in pERK-positive neuroblastoma xenografts short-term, with pERK status serving as potential treatment biomarker. However, tumors develop acquired resistance during prolonged treatment, with pERK reactivation observed after six weeks, highlighting need for combination strategies.